APTAMER GROUP PLC

Share Issue/Capital Change • Aug 19, 2025

National Storage Mechanism | Additional information

RNS Number : 7865V

Aptamer Group PLC

19 August 2025

19 August 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Exercise of warrants

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce that it has received notice to exercise warrants over a total of 36,000,000 new ordinary shares of £0.001 each in the Company ("Warrant Shares") at an exercise price of £0.002 per Warrant Share, raising £72,000 for the Company.

Total voting rights

An application will be made for the admission of these shares to trading on AIM, which is expected to become effective on or around 22 August 2025.

Immediately following Admission, the Company will have 2,696,978,377 ordinary shares of £0.001 each in issue.  The Company does not hold any shares in treasury, and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

- Ends -

For further information, please contact: 

Aptamer Group plc    Dr Arron Tolley, Chief Executive Officer	+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser      Andrew Emmott / Jade Bayat	+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker      James Pope / Andrew Thacker	+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations Sarah Hollins	+44 (0) 113 730 3896

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

​Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to  https://aptamergroup.com/investors/investor-news-email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGZGMRVRDGKZM